Your search
Results 2 resources
-
Recent reports pointed out that the application of optical spectroscopy in the field of liquid biopsy has aroused great interest among researchers and demonstrated the potential of its clinical application. We report a preliminary investigation on the visible resonance Raman (VRR) spectra of human brain blood liquid collected from the scalp and around the meningeal tumor during surgery and a set of venous blood samples from healthy people and glioma grade III patients using a portable VRR-LRRTM, HR800, HR-Evolution and WITec300 Raman systems in vivo and ex vivo. The biochemical fingerprints and molecular biomarkers were found. These findings indicate that if VRR spectroscopy technology is combined with polymerase chain reaction (PCR) or genetic molecular biomarker methods (VRR-PCR), it will greatly increase the possibility for its clinical application. © 2021 SPIE.
-
Based on Visible Resonance Raman (VRR) method, we have developed a novel label-free portable VRR LRR2000 Raman analyzer with a portable fiber-optic probe and used it for the classification of human gliomas ex vivo and for the analysis of changes in tumor chemical compositions in molecular level. The purpose of this study was to examine the performance of the LRR2000 Raman analyzer as an optical biopsy tool for detecting human brain tumors compared to the commercial laboratory HR800 and WITec300 micro confocal Raman spectroscopy instruments. As of 2018, a total 1,938 VRR spectra were collected using LRR2000, HR800 and WITec300 Raman system, ex vivo. Identification of the four grades of glioma tumors and control tissues was performed based on the characteristic native molecular fingerprints. LRR2000 demonstrated consistent diagnostic results with HR800 and WITec300 Raman systems. LRR2000 showed the advantages of high speed, convenience and low cost compared to the two confocal micro Raman systems. Using artificial intelligence (AI)-based analysis of part of the data, the cross-validated accuracy for identifying glioma tumors is ~90% compared with gold standard histopathology examination.